Literature DB >> 507759

Evaluation of insulin receptor in myotonic dystrophy.

B W Festoff, W V Moore.   

Abstract

Only 2 of 6 patients with myotonic dystrophy had glucose intolerance and hyperinsulinemia. All, however, had markedly reduced insulin binding to specific receptors on circulating monocytes. A significant difference in receptor affinity for insulin was observed, but the difference in affinity was not as marked as that in the amount of 125I-insulin bound per cell, which was sixfold greater in control cells. No evidence for a circulating factor competing with insulin for binding sites could be demonstrated. These alterations in binding did not directly correlate with glucose intolerance or hyperinsulinemia and are consistent with a postulated generalized membrane defect. Study of the insulin receptor in this disorder may uncover regulatory mechanisms in normal and pathological conditions, including myotonic dystrophy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 507759     DOI: 10.1002/ana.410060114

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  4 in total

1.  Lymphocyte capping in myotonic dystrophy.

Authors:  G L Walker; U Karagol; E C Mathieson; R J Lane; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-01       Impact factor: 10.154

2.  Insulin receptors in myotonic dystrophy: a study with mononuclear leucocytes and erythrocytes.

Authors:  P Fratino; G Bellomo; R Bellazzi; P L Nicotera; G Sandrini; G Nappi
Journal:  Ital J Neurol Sci       Date:  1982-07

3.  Abnormal regulation of monocyte insulin-binding affinity after glucose ingestion in patients with myotonic dystrophy.

Authors:  R T Moxley; J N Livingston; D H Lockwood; R C Griggs; R L Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

Review 4.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.